Mitsubishi Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice.
Information RADICAVA ORS now available in U.S. for treatment of ALS
June 16, 2022
Mitsubishi Tanabe Pharma America Inc., a sales subsidiary of Mitsubishi Tanabe Pharma Corporation announced RADICAVA ORS is now available in the United States.
Press Release[PDF:114KB](June 15, 2022)